On the immunology side, Mesoblast is clearly making a huge bet with the acquisition of Prochymal. The company is saying Prochymal works, and that if it runs the proper clinical trials, Prochymal is an approvable product in the U.S. for graft-versus-host disease (GvHD). . .we'd love to see Mesoblast launch a U.S. clinical trial with Prochymal in GvHD, where an approved therapy is so desperately needed."
Mesoblast just reported strong data, not in the cardiovascular space but in degenerative intervertebral disc disease. It showed a high efficacy rate with an associated p-value, or a statistically significant result, which demonstrates it's not just luck. [This] tells me that these cells are really working. In addition, the result is further supported by two earlier trials in a related but different indication, spinal fusion. The two trials reported at the end of last year showed the cell therapy worked just as well as autologous bone graft to successfully fuse a spine. . .if the Mesoblast MPCs show a restoration of vertebral height in humans, many orthopedic surgeons have told me that would be the Holy Grail."